Recro Pharma (REPH) Issues Earnings Results

Recro Pharma (NASDAQ:REPH) posted its earnings results on Wednesday. The specialty pharmaceutical company reported ($0.64) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.67) by $0.03, MarketWatch Earnings reports. Recro Pharma had a negative net margin of 75.19% and a negative return on equity of 144.84%. The firm had revenue of $18.28 million for the quarter, compared to analyst estimates of $16.77 million. Recro Pharma updated its FY 2018 guidance to EPS.

REPH traded up $0.16 during trading on Friday, reaching $7.35. 115,327 shares of the company’s stock were exchanged, compared to its average volume of 150,451. Recro Pharma has a one year low of $4.78 and a one year high of $13.05. The company has a debt-to-equity ratio of 2.22, a current ratio of 1.59 and a quick ratio of 1.42. The firm has a market capitalization of $147.30 million, a price-to-earnings ratio of -3.69 and a beta of -0.51.

A number of equities research analysts have weighed in on REPH shares. Oppenheimer set a $18.00 target price on shares of Recro Pharma and gave the stock a “buy” rating in a report on Wednesday, August 8th. ValuEngine lowered shares of Recro Pharma from a “buy” rating to a “hold” rating in a report on Monday, September 17th. Janney Montgomery Scott set a $13.00 target price on shares of Recro Pharma and gave the stock a “buy” rating in a report on Monday, October 1st. Zacks Investment Research raised shares of Recro Pharma from a “hold” rating to a “strong-buy” rating and set a $8.25 target price on the stock in a report on Wednesday. Finally, Piper Jaffray Companies set a $10.00 target price on shares of Recro Pharma and gave the stock a “buy” rating in a report on Thursday. Nine analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $12.88.

A number of institutional investors and hedge funds have recently bought and sold shares of REPH. Wells Fargo & Company MN increased its stake in Recro Pharma by 45.4% in the 1st quarter. Wells Fargo & Company MN now owns 76,832 shares of the specialty pharmaceutical company’s stock valued at $846,000 after purchasing an additional 23,984 shares in the last quarter. JPMorgan Chase & Co. increased its stake in Recro Pharma by 211.8% in the 1st quarter. JPMorgan Chase & Co. now owns 98,751 shares of the specialty pharmaceutical company’s stock valued at $1,087,000 after purchasing an additional 67,078 shares in the last quarter. The Manufacturers Life Insurance Company increased its stake in Recro Pharma by 6,480.5% in the 1st quarter. The Manufacturers Life Insurance Company now owns 235,712 shares of the specialty pharmaceutical company’s stock valued at $2,595,000 after purchasing an additional 232,130 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new position in Recro Pharma in the 1st quarter valued at approximately $139,000. Finally, Millennium Management LLC purchased a new position in Recro Pharma in the 1st quarter valued at approximately $3,060,000. 54.79% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Recro Pharma (REPH) Issues Earnings Results” was first posted by WKRB News and is the property of of WKRB News. If you are viewing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this article can be accessed at https://www.wkrb13.com/2018/11/09/recro-pharma-reph-issues-earnings-results.html.

About Recro Pharma

Recro Pharma, Inc, a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. The company's lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.

Recommended Story: Why is the conference call important?

Earnings History for Recro Pharma (NASDAQ:REPH)

Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply